4/A: Aytu BioPharma Director, Vivian H. Liu, Reports Amended Statement of Changes in Beneficial Ownership

Vivian H. Liu, a director of Aytu BioPharma, filed an amended Form 4 to correct the total shares beneficially owned following a transaction on August 11, 2023.

Summary

• Vivian H. Liu, a director of Aytu BioPharma, filed an amended Form 4 with the SEC.
• The amendment corrects the total number of common shares beneficially owned following a transaction on August 11, 2023.
• On August 11, 2023, Liu acquired 1,500 common shares.
• These shares were granted as restricted shares, vesting in installments.
• Specifically, 1/3 of the shares vest on August 11, 2024, with the remaining shares vesting in eight equal installments every three months starting November 11, 2024.
• The filing also reflects a 1-for-20 reverse stock split that Aytu BioPharma effected on January 6, 2023.
• Following the reported transaction, Liu beneficially owns 8,325 common shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The acquisition of restricted shares by a director could be seen as a positive sign of alignment with the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is an amendment to correct a previous filing, which is not uncommon.

Stakeholder Impact

• Shareholders are informed about the transactions of a company director, promoting transparency.

Key Dates

Keywords

Form 4, Beneficial Ownership, Aytu BioPharma, Director, Vivian H. Liu, Restricted Shares, Reverse Stock Split